Xeris Biopharma Holdings, Inc. (XERS) › Cash & EquivalentsXeris Biopharma Holdings, Inc. (XERS) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2019-12-31: $19.52M2020-12-31: $37.60M2021-12-31: $67.27M2022-12-31: $121.97M2023-12-31: $67.45M2024-12-31: $71.62M2025-12-31: $111.04M$111.04M2019-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$111.04M+55.0%2026-03-02Balance as of period end2024-12-31$71.62M+6.2%2026-03-02Balance as of period end2023-12-31$67.45M-44.7%2026-03-02Balance as of period end2022-12-31$121.97M+81.3%2024-03-06Balance as of period end2021-12-31$67.27M+78.9%2023-03-08Balance as of period end2020-12-31$37.60M+92.6%2022-03-11Balance as of period end2019-12-31$19.52M—2022-03-11Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)